A Matter of Genes: The Hurdles of Gene Therapy for Epilepsy

Selene Ingusci¹, Stefano Cattaneo², Gianluca Verlengia¹,², Silvia Zucchini¹,³, and Michele Simonato¹,²

¹ Department of Medical Sciences and National Institute of Neuroscience, University of Ferrara, Ferrara, Italy
² School of Medicine, University Vita-Salute San Raffaele, Milan, Italy
³ Technopole of Ferrara, LTAA Laboratory for the Technologies for Advanced Therapies, Ferrara, Italy

Correspondence: Michele Simonato, Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy; School of Medicine, University Vita-Salute San Raffaele, 20132 Milan, Italy; e-mails: michele.simonato@unife.it; simonato.michele@hsr.it

Abstract
Gene therapy has recently advanced to the level of standard of care for several diseases. However, its application to neurological disorders is still in the experimental phase. In this review, we discuss recent advancements in the field that provide optimism on the possibility to have first-in-human studies for gene therapy of some forms of epilepsy in the not so distant future.

Keywords
Gene therapy, Viral vectors

Introduction
As is well known, current therapies for epilepsy are largely unsatisfactory.¹ In spite of the many available antiepileptic drugs and of other therapeutic approaches (surgery, brain stimulation, ketogenic diet, etc.), about one-third of the patients do not get control of their seizures. We do not have any treatment able to prevent epilepsy development in at-risk individuals. We do not have adequate control of epilepsy comorbidities that heavily affect the quality of life of patients. Many devastating forms of epilepsy are resistant to any treatment. And the list could continue.

Within this scenario, the search for new, alternative therapeutic approaches is always a priority, and gene therapy is often a consideration. In principle, the idea is simple: Use some kind of vector to transfer the DNA encoding some “therapeutic” protein(s) into the diseased cells, in order to permanently heal them. There are different types of DNA that one could desire to transfer, reflecting different therapeutic strategies. The most obvious is the healthy variant of a defective gene, which could be an option in some genetic forms of epilepsy. But it would also be possible to attempt healing the defective gene using gene editing technologies, including clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9-mediated genetic modification, and gene activation or inhibition (CRISPRa or CRISPRi). Another option could be to transfer genes that can modify cell (or circuit) function and control hyperexcitability, such as channels, neurotransmitters, or receptors. Finally, one could transfer genes encoding proteins that render the cell sensitive to specific drugs (chemogenetics) or to light stimulation (optogenetics).

In sum, there are multiple diverse options and strategies on stage. But are these doable? Can they be applied to all forms of epilepsy? Which forms of epilepsy may represent low hanging fruit for starting a program of clinical translation? Answering the first question means having at hand systems of gene transfer (vectors) that are safe, allow transfer of a sufficiently large DNA cargo, and ensure robust, lasting, and regulated expression of the therapeutic gene(s) in a specific target cell. The other questions underlie other key problems, for example, the fact that, for focal epilepsies, it may be sufficient to inject the vector and express the therapeutic gene(s) in a relatively restricted brain area, whereas in generalized epilepsies there could be a need to obtain widespread expression in the whole brain.

Below, we briefly summarize the state of the art of vector development for gene therapy and the results of preclinical studies in epilepsy models. We then describe some recent
advances that may be implemented in epileptology, moving the field closer to a much-awaited clinical application.

Viral Vectors for the Central Nervous System

There are 2 main classes of gene delivery tools, nonviral and viral vectors, each endowed with specific advantages and disadvantages. Compared with viral vectors, nonviral vectors tend to have lower immunogenicity, due to the absence of preexisting immunity, larger payload capacity, and easier production techniques. However, their major drawback is the low transduction efficiency.

In contrast, viral vectors exploit the viruses’ highly evolved strategies for efficient transfer of foreign DNA into eukaryotic cells. Among different viruses engineered and tested for gene therapy, the most promising candidates for central nervous system (CNS) applications seem to be adeno-associated viruses, lentiviruses and herpes viruses (Table 1). Adeno-associated viruses (AAV) are small single-stranded DNA viruses. In spite of their limited cargo capacity (4.5 kb), AAV vectors are the most commonly used in clinical trials for CNS gene therapy because they exhibit low immunogenicity, no pathogenicity, and long-lasting transgene expression in both dividing and nondividing cells. Several AAV serotypes have been identified and developed, based on capsid variants that confer different tropisms, antigenic profiles, and transduction efficiency. For example, the AAV1, AAV2, AAV5, and AAV8 serotypes display a marked neuronal tropism, whereas the AAV9 serotype can cross the blood–brain barrier (BBB) after peripheral administration. A tropism shift from neurons to glia is observed in the mature brain, indicating that brain development should be considered for therapeutic applications. All these features can be modulated and improved by combining 2 or more different serotypes, by mutation of capsid tyrosine residues, or by fusing peptides to capsid proteins. One major problem with AAV vectors is the inactivation by neutralizing antibodies. However, chemical compounds or association with exosomes have been tested to shield the capsid from neutralizing antibodies.

Lentiviruses (LV) are integrating single-stranded RNA viruses, capable of transducing nondividing and dividing cells. Most LV vectors derive from human immunodeficiency virus and have a transgene payload capacity of about 9 kb. Pseudotyping their envelope with glycoproteins derived from herpes simplex virus (HSV), rabies, or vesicular stomatitis virus allows one to modify, improve, and refine cellular tropism and transduction efficiency. Insertional mutagenesis is a potential risk. Nonintegrating LV vectors have been developed by introducing mutations in the integrase gene, such that the viral genome persists in the host cell mostly in an episomal form. The HSV vectors are double-stranded DNA viruses that can be divided into 3 main categories: replication-competent (employed in cancer), replication-defective, and amplicon vectors, carrying a DNA plasmid instead of the viral genome. Both replication-defective and amplicon vectors display natural neuronal tropism and high payload capacity, up to 50 and 150 kb, respectively, which allows the insertion of large transgenes and regulation systems. These features, together with a high transduction efficiency, the ability of both anterograde and retrograde transport, and the episomal nonintegrating genome, make HSV vectors an attractive tool for CNS disorders. Their downsides are the residual toxicity and a relatively transient transgene expression. In addition, preparations of amplicon vectors remain contaminated by a small percentage of helper virus. However, new generation vectors seem to overcome these problems (Table 1 and see below).

Table 1. Viral Vectors.

| Family of wild-type virus | Adeno-Associated Vectors | Lentiviral Vectors | “Classic” Herpes Virus Vectors | “New” Herpes Virus Vectors |
|---------------------------|--------------------------|-------------------|-------------------------------|---------------------------|
| Infection/tropism         | Dividing and nondividing cells | Dividing and nondividing cells | Dividing and nondividing cells | Dividing and nondividing cells |
| Genetic material          | ssDNA                   | ssRNA              | dsDNA                         | dsDNA                      |
| Host–genome interaction   | No                       | Yes                | No                            | No                         |
| Packaging capacity        | 4.5 kb b                | 9 kb               | 50-150 kb                     | 50 kb                      |
| Toxicity                  | Low                     | Low                | Moderate                      | Low                        |
| Transgene expression      | Long-lasting            | Long-lasting       | Transient                     | Long-lasting               |
| Main limitation           | Very small packaging capacity | Small packaging capacity | Integration                 | Not yet clinically tested |
| Main advantages           | Noninflammatory         | Persistent transgene expression | Large payload capacity | Large payload capacity |

Abbreviations: ds, double-stranded; ss, single-stranded.
aSome integration at very low frequency.
bPackaging capacity may be increased by splitting the transgene cassette into 2 to 3 viruses.
Gene Therapy Approaches in Animal Models of Epilepsy

All work on gene therapy for epilepsy thus far has been performed in animal models and by focal administration of vectors. In most cases, the focus has been on post-status epilepticus (SE) models. One study explored the antiepileptogenic effect of HSV vector-mediated delivery of neurotrophic factors such as fibroblast growth factor 2 and brain-derived neurotrophic factor in the pilocarpine model. Injection of this vector into the hippocampus during the latent period (3 days after SE) attenuated seizure-induced damage, favored a more physiological neurogenesis, and highly reduced the occurrence of spontaneous recurrent seizures (SRSs).

All other studies focused on the chronic period, when animals were experiencing SRSs, and used seizure frequency as the primary outcome measure. This approach has greater translational potential, as it may be offered to individuals with drug-resistant focal seizures that cannot be treated surgically. Overall, the aim of all these studies was to increase inhibition in the epileptogenic area, but strategies were diverse. For example, some used AAV vectors to downregulate excitatory receptor function (by transferring antisense NR1, an essential subunit of the NMDA receptors) or to upregulate inhibitory receptor function (by transferring the α-1 subunit of the GABA<sub>A</sub> receptor). Others used LV vectors to overexpress potassium channels or halorhodopsin for inhibitory optogenetic stimulation. Or, using AAV vectors, one group expressed a modified muscarinic receptor (hM4Di) to obtain seizure suppression by systemic administration of the hM4Di selective, normally inactive agonist clozapine-N-oxide. Yet another strategy was to express a genetically modified glutamate-gated Cl<sup>−</sup> channel.

All these strategies proved effective. However, a common challenge is the ability to express the transgene in a specific cell population, because inhibiting inhibitory neurons would favor the occurrence of seizures. To avoid this problem, therefore, these authors drove expression of their transgenes by promoters specifically active in excitatory neurons, in an attempt to bias expression toward (and thereby preferentially inhibit) excitatory neurons. As discussed below, this is a reasonable but imperfect solution.

One alternative strategy is the expression of a soluble inhibitory factor that can be secreted by the transduced cells: In this case, seizure control may be achieved without targeting specific cells, provided that the receptors for that factor are found in the injected area. Several studies have demonstrated that overexpression in the hippocampus of inhibitory neuropeptides (neuropeptide Y [NPY], galanin, or somatostatin) exerts antiseizure effects in epilepsy models (data on NPY and galanin reviewed in Simonato, Simonato et al, and Kullmann et al; for somatostatin, see Natarajan et al).

Among these neuropeptides, NPY seems the most promising translationally because it is the most effective in suppressing seizure-like activity in slices from the human epileptic hippocampus. However, a complication (and an opportunity) for NPY is that its effects are mediated by multiple receptors, some proepileptic (the Y1 subtype), others (Y2 and Y5) antiepileptic. A combined administration of an AAV vector expressing NPY with one expressing the Y2 or one expressing the Y5 receptor produced much stronger reductions in seizure frequency than NPY alone.

Looking Forward

Altogether, the results of preclinical studies in epilepsy models suggest optimism as to the possibility of translation in humans. This optimism is sustained by recent advancements in clinical experimentation for other CNS diseases, in vector design, and in targeting and regulation strategies.

Advancements in clinical experimentation for CNS diseases. The main obstacles on the way to human translation are the complexity and heterogeneity of the target tissue, the presence of the BBB, and the safety of viral vectors. However, successful reports from experimentation for other CNS diseases are helping to concretely chart out a roadmap toward the first-in-man gene therapy for intractable epilepsy.

The direct intraparenchymal infusion of viral vectors has been successfully explored in a number of clinical studies for neurological disorders. One of the most promising envisaged the bilateral injection in the subthalamic nucleus of patients affected by medically refractory Parkinson disease with a mix of recombinant AAVs encoding GABA synthesizing enzymes (GAD65 or GAD67). Upon assessment of safety and tolerability, this study became the first double-blinded and randomized trial of gene therapy for the CNS, showing beneficial effects on motor function that persisted up to 12 months.

A more recent study explored the use of an LV gene therapy vector for the simultaneous delivery into the striatum of 3 key enzymes for dopamine biosynthesis, providing a local and sustained novel source of dopamine from nondopaminergic transduced cells. A first trial positively verified the safety profile of this treatment, which was subsequently confirmed in an 8-year follow-up along with a moderate improvement of motor function.

Another major advancement was the discovery of the ability of the AAV9 serotype to cross the BBB, which makes it potentially usable to treat genetic neurological diseases by transferring the healthy allele to the brain in a widespread manner. In a phase 1 clinical study, a group of patients affected by spinal muscular atrophy type-1 (SMA1), a monogenic disorder caused by mutation of the survival motor neuron-1 (SMN<sub>1</sub>) gene, has been successfully treated by a single, systemic dose of a recombinant AAV9 vector carrying the SMN<sub>1</sub> gene. In principle, this approach may be used for some monogenetic forms of epilepsy, such as Dravet syndrome (DS). Similar to SMA1, DS is generally caused by heterozygous mutations of the gene encoding the voltage-gated sodium channel α1 subunit (SCN1A). Unfortunately, however, neither the AAV nor the LV vectors can accommodate the entire SCN1A expression cassette in a single vector. To overcome this hurdle, the AAV...
Defective vectors, devoid of all viral immediately early genes, come these problems (Table 1). These are highly replication-recently developed a new generation of HSV vectors that over-achieving persistent expression in the CNS. However, we have AAV and LV vectors do not combine all these features, while and/or multiple inserts, safety, lasting transgene expression, and mechanisms to regulate expression. As described above, HSV vectors have been relatively overlooked so far because of concerns about cytotoxicity, immunogenicity, and difficulty in achieving persistent expression in the CNS. However, we have recently developed a new generation of HSV vectors that overcome these problems (Table 1). These are highly replication-defective vectors, devoid of all viral immediately early genes, in which viral gene expression is virtually absent. We found that inserting an expression cassette in a specific locus of the genome (the ICP4 locus) permits robust and long-term reporter gene expression in a diversity of neurons following stereotactic injection in the brain. Virus infection did not cause any neurotoxicity or inflammatory infiltrates. Therefore, these are high-capacity vectors capable of safe, long-term transgene expression in the brain, opening up the possibility for therapeutic intervention into CNS diseases that require transfer of large amounts of DNA.

**Advances in vector design.** Vectors for CNS gene therapy should be highly refined, in order to ensure delivery to specific cell types, efficacy of transgene expression, capacity to host large and/or multiple inserts, safety, lasting transgene expression, and mechanisms to regulate expression. As described above, AAV and LV vectors do not combine all these features, while HSV vectors have been relatively overlooked so far because of concerns about cytotoxicity, immunogenicity, and difficulty in achieving persistent expression in the CNS. However, we have recently developed a new generation of HSV vectors that overcome these problems (Table 1). These are highly replication-defective vectors, devoid of all viral immediately early genes, in which viral gene expression is virtually absent. We found that inserting an expression cassette in a specific locus of the genome (the ICP4 locus) permits robust and long-term reporter gene expression in a diversity of neurons following stereotactic injection in the brain. Virus infection did not cause any neurotoxicity or inflammatory infiltrates. Therefore, these are high-capacity vectors capable of safe, long-term transgene expression in the brain, opening up the possibility for therapeutic intervention into CNS diseases that require transfer of large amounts of DNA.

**Advances in cell targeting and in regulation strategies.** Other key advances were recently made for achieving a robust expression of the transgenes in a cell-specific manner, avoiding the risk of off-target effects. As mentioned above, the “classic” approach is to drive transgene expression through promoters that are active only in the desired cell type. For example, candidates to restrict gene expression in inhibitory neurons are the GAD65 or GAD67 promoters that code for the enzyme that catalyzes the transformation of glutamate into GABA. However, this procedure does not completely ensure selectivity of expression and, in addition, the size of many full-length promoters is too large for most viral vectors. An alternative and more efficient strategy was recently proposed, based on the encoding of microRNA target motifs downstream of the transgene. The introduction of multiple target motifs for microRNAs expressed in off-target cells silenced transgene expression in these cells, thereby achieving highly specific expression in the desired cell type.

Another important advance involves the regulation of gene expression. Mechanisms of autoregulation are important requirements for clinical translation because they reduce the risk of negative effects on physiological brain circuitries. Lieb et al cloned into an LV vector an optimized sequence encoding a glutamate-gated chloride channel with an EC\textsubscript{50} for glutamate of about 10 \(\mu\text{M}\), that is, high concentrations that would be reached at extrasynaptic levels only during seizures. When injected in the rat neocortex, this vector led to a potent attenuation of evoked and spontaneous seizures, in the absence of alterations in normal brain function.

**Conclusions**

Although gene therapy is becoming an established approach for an increasing number of diseases, its application to CNS disorders still poses formidable challenges that are not yet completely overcome. Although it will be essential to sort out all possible problems before clinical testing, the good news is that the field is progressing rapidly and it seems plausible that the time for a first-in-man gene therapy for epilepsy is not too far anymore.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The work by the authors described in this review was supported by the FP7-HEALTH project 620120 (EPITARGET).

**References**

1. Simonato M, Brooks-Kayal AR, Engel J Jr, et al. The challenge and promise of anti-epileptic therapy development in animal models. *Lancet Neurol*. 2014;13(9):949-960.
2. Pack DW, Hoffman AS, Pun S, Stayton PS. Design and development of polymers for gene delivery. *Nat Rev Drug Discov*. 2005;4(7):581-593.
3. Mintzer MA, Simanek EE. Nonviral vectors for gene delivery. *Chem Rev*. 2009;109(2):259-302.
4. Kaplitt MG, Leone P, Samulski RJ, et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. *Nat Genet*. 1994;8(2):148-154.
5. McCown TJ, Xiao X, Li J, Breese GR, Samulski RJ. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. *Brain Res*. 1996;713(1-2):99-107.
6. Choudhury SR, Harris AF, Cabral DJ, et al. Widespread central nervous system gene transfer and silencing after systemic delivery of novel AAV-AS vector. *Mol Ther*. 2016;24(4):726-735.
7. Kaeppel C, Beattie SG, Franz R, et al. A largely random AAV integration profile after LPLD gene therapy. *Nat Med*. 2013;19(7):889-896.
8. Castle MJ, Turunen HT, Vandenbergh LH, Wolfe JH. Controlling AAV tropism in the nervous system with natural and engineered capsids. *Methods Mol Biol*. 2016;1382:133-149.
9. Harding TC, Dickinson PJ, Roberts BN, et al. Enhanced gene transfer efficiency in the murine striatum and an orthotopic
10. Weinberg MS, Blake BL, Samulski RJ, McCown TJ. The influence of epileptic neunopathology and prior peripheral immunity on CNS transduction by rAAV2 and rAAV5. *Gene Ther.* 2011;18(10):961-968.

11. Dodiya HB, Bjorklund T, Stansell J 3rd, Mandel RJ, Kirik D, Kordower JH. Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. *Mol Ther.* 2010;18(3):579-587.

12. Burger C, Gorbatyuk OS, Velardo MJ, et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. *Mol Ther.* 2004;10(2):302-317.

13. Davidson BL, Stein CS, Heth JA, et al. Recombinant adenovirus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. *Proc Natl Acad Sci U S A.* 2000;97(11):3428-3432.

14. Klein RL, Dayton RD, Tatom JB, Henderson KM, Henning PP. AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method. *Mol Ther.* 2008;16(1):89-96.

15. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. *Nat Biotechnol.* 2009;27(1):59-65.

16. Kanaan NM, Sellnow RC, Boye SL, et al. Rationally engineered AAV capsids improve transduction and volumetric spread in the CNS. *Mol Ther Nucleic Acids.* 2017;8:184-197.

17. Hudry E, Martin C, Gandhi S, et al. Exosome-associated AAV vector as a robust and convenient neuroscience tool. *Gene Ther.* 2016;23(11):819.

18. Bukrinsky MI, Haggerty S, Dempsey MP, et al. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. *Nature.* 1993;365(6447):666-669.

19. Liu YP, Berkhsout B. HIV-1-based lentiviral vectors. *Methods Mol Biol.* 2014;1087:273-284.

20. Wong LF, Azzouz M, Walmsley LE, et al. Transduction patterns of pseudotyped lentiviral vectors in the nervous system. *Mol Ther.* 2004;9(1):101-111.

21. Mazarakis ND, Azzouz M, Rohll JB, et al. Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. *Hum Mol Genet.* 2001;10(19):2109-121.

22. Kato S, Inoue K, Kobayashi K, et al. Efficient gene transfer via retrograde transport in rodent and primate brains using a human immunodeficiency virus type I-based vector pseudotyped with rabies virus glycoprotein. *Hum Gene Ther.* 2007;18(11):1141-151.

23. Trabalza A, Eleftheriadou I, Sgourou A, et al. Enhanced central nervous system transduction with lentiviral vectors pseudotyped with RVG/HIV-1gp41 chimeric envelope glycoproteins. *J Virol.* 2014;88(5):2877-890.

24. Carpentier DC, Vevis K, Trabalza A, et al. Enhanced pseudotyping efficiency of HIV-1 lentiviral vectors by a rabies/vesicular stomatitis virus chimeric envelope glycoprotein. *Gene Ther.* 2012;19(7):761-774.

25. Berges BK, Wolfe JH, Fraser NW. Transduction of brain by herpes simplex virus vectors. *Mol Ther.* 2007;15(1):20-29.

26. Diefenbach RJ, Miranda-Saksema M, Douglas MW, Cunningham AL. Transport and egress of herpes simplex virus in neurons. *Rev Med Virol.* 2008;18(1):35-51.

27. Goverdhsa S, Puntel M, Xiong W, et al. Regulatable gene expression systems for gene therapy applications: progress and future challenges. *Mol Ther.* 2005;12(2):189-211.

28. Epstein AL. Progress and prospects: biological properties and technological advances of herpes simplex virus type 1-based amplicon vectors. *Gene Ther.* 2009;16(6):709-715.

29. Paradiso B, Marconi P, Zucchini S, et al. Localized delivery of fibroblast growth factor-2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model. *Proc Natl Acad Sci U S A.* 2009;106(17):7191-7196.

30. Haberman R, Criswell H, Snowdy S, et al. Therapeutic liabilities of in vivo viral vector tropism: adeno-associated virus vectors, NMDAR1 antisense, and focal seizure sensitivity. *Mol Ther.* 2002;6(4):495-500.

31. Raol YH, Lund IV, Bandopadhyay S, et al. Enhancing GABA(A) receptor alpha 1 subunit levels in hippocampal dentate gyrus inhibits epilepsy development in an animal model of temporal lobe epilepsy. *J Neurosci.* 2006;26(44):11342-11346.

32. Wykes RC, Heeroma JH, Mantoan L, et al. Optogenetic and potassium channel gene therapy in a rodent model of focal neocortical epilepsy. *Sci Transl Med.* 2012;4(161):161ra152.

33. Katzel D, Nicholson E, Schorge S, Walker MC, Kullmann DM. Chemical-genetic attenuation of focal neocortical seizures. *Nat Commun.* 2014;5:3847.

34. Lieb A, Qiu Y, Dixon CL, et al. Biochemical autoregulatory gene therapy for focal epilepsy. *Nat Med.* 2018;24(9):1324-1329.

35. Simonato M. Gene therapy for epilepsy. *Epilepsy Behav.* 2014;38:125-130.

36. Simonato M, Bennett J, Boulis NM, et al. Progress in gene therapy for neurological disorders. *Nat Rev Neurol.* 2013;9(5):277-291.

37. Kullmann DM, Schorge S, Walker MC, Wykes RC. Gene therapy in epilepsy—is it time for clinical trials? *Nat Rev Neurol.* 2014;10(5):300-304.

38. Natarajan G, Leibowitz JA, Zhou J, et al. Adeno-associated viral vector-mediated preprosomatostatin expression suppresses induced seizures in kindled rats. *Epilepsy Res.* 2017;130:81-92.

39. Ledri M, Sorensen AT, Madsen MG, et al. Differential effect of neuropeptides on excitatory synaptic transmission in human epileptic hippocampus. *J Neurosci.* 2015;35(26):9622-9631.

40. Vezzani A, Sperk G, Colmers WF. Neuropeptide Y: emerging evidence for a functional role in seizure modulation. *Trends Neurol.* 1999;22(1):25-30.

41. Woldbye DP, Angehagen M, Gotzsche CR, et al. Adeno-associated viral vector-induced overexpression of neuropeptide Y2 receptors in the hippocampus suppresses seizures. *Brain.* 2010;133(9):2778-2788.

42. Gotzsche CR, Nikitidou L, Sorensen AT, et al. Combined gene overexpression of neuropeptide Y, its receptor Y5 in the
43. Muramatsu S, Fujimoto K, Kato S, et al. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson’s disease. *Mol Ther*. 2010;18(9):1731-1735.

44. Christine CW, Starr PA, Larson PS, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. *Neurology*. 2009;73(20):1662-1669.

45. Eberling JL, Jagust WJ, Christine CW, et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. *Neurology*. 2008;70(21):1980-1983.

46. Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial. *Lancet*. 2007;369(9579):2097-2105.

47. LeWitt PA, Rezai AR, Leehey MA, et al. AAV2-GAD gene therapy for advanced Parkinson’s disease: a double-blind, sham-surgery controlled, randomised trial. *Lancet Neurol*. 2011;10(4):309-319.

48. Niethammer M, Tang CC, LeWitt PA, et al. Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson’s disease. *JCI Insight*. 2017;2(7): e90133.

49. Palfi S, Gurruchaga JM, Ralph GS, et al. Long-term safety and tolerability of ProSavina, a lentiviral vector-based gene therapy for Parkinson’s disease: a dose escalation, open-label, phase 1/2 trial. *Lancet*. 2014;383(9923):1138-1146.

50. Palfi S, Gurruchaga JM, Lepetit H, et al. Long-term follow-up of a phase I/II study of prosavin, a lentiviral vector gene therapy for Parkinson’s disease. *Hum Gene Ther Clin Dev*. 2018;29(3):148-155.

51. Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. *N Engl J Med*. 2017;377(18):1713-1722.

52. Duan D, Sharma P, Yang J, et al. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. *J Virol*. 1998;72(11):8568-8577.

53. Duan D, Yan Z, Yue Y, Engelhardt JF. Structural analysis of adeno-associated virus transduction circular intermediates. *Virology*. 1999;261(1):8-14.

54. Yan Z, Zhang Y, Duan D, Engelhardt JF. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. *Proc Natl Acad Sci U S A*. 2000;97(12):6716-6721.

55. Duan D, Yue Y, Engelhardt JF. Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. *Mol Ther*. 2001;4(4):383-391.

56. Ghosh A, Yue Y, Lai Y, Duan D. A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner. *Mol Ther*. 2008;16(2):524-541.

57. Miyagawa Y, Marino P, Verlengia G, et al. Herpes simplex viral-vector design for efficient transduction of nonneuronal cells without cytotoxicity. *Proc Natl Acad Sci U S A*. 2015;112(13):E1632-E1641.

58. Verlengia G, Miyagawa Y, Ingusci S, Cohen JB, Simonato M, Glorioso JC. Engineered HSV vector achieves safe long-term transgene expression in the central nervous system. *Sci Rep*. 2017;7(1):1507.

59. Nathanson JL, Jappelli R, Scheeff ED, et al. Short promoters in viral vectors drive selective expression in mammalian inhibitory neurons, but do not restrict activity to specific inhibitory cell-types. *Front Neural Circuits*. 2009;3:19.

60. Keaveney MK, Tseng HA, Ta TL, Gritton HJ, Man HY, Han X. A microRNA-based gene-targeting tool for virally labeling interneurons in the rodent cortex. *Cell Rep*. 2018;24(2):294-303.